TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04914910

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimed 780G insulin pump
Description: This will be a 14-week, open-label, randomised, parallel-group, controlled trial comparing the efficacy of an AHCL system (MiniMed 780G, Medtronic Diabetes, Northridge, CA) with usual care (i.e., a person's usual insulin pump and CGM/isCGM system). After the 14-week trial period, the control group switches to treatment with the MiniMed 780G system. The intervention group continues with the MiniMed 780G system. Both groups are monitored for another 14 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Minimed 780G insulin pump
Description: This will be a 14-week, open-label, randomised, parallel-group, controlled trial comparing the efficacy of an AHCL system (MiniMed 780G, Medtronic Diabetes, Northridge, CA) with usual care (i.e., a person's usual insulin pump and CGM/isCGM system). After the 14-week trial period, the control group switches to treatment with the MiniMed 780G system. The intervention group continues with the MiniMed 780G system. Both groups are monitored for another 14 weeks.
Study: NCT05381584

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopy
Description: laparoscopy will be done under anesthesia for management for cases with blind vagina

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopy
Description: laparoscopy will be done under anesthesia for management for cases with blind vagina
Study: NCT05408416

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preoperative group and intraoperative group
Description: ranibizumab injection (0.5mg/0.05ml) 3-5 days before vitrectomy or ranibizumab injection (0.5mg/0.05ml) at the end of vitrectomy
Study: NCT04975100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarcosine and SSRI
Description: Patients in the test group will get Sarcosine 500 mg capsules once daily as an add-on to ongoing SSRI treatment
Study: NCT05408416

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preoperative group and intraoperative group
Description: ranibizumab injection (0.5mg/0.05ml) 3-5 days before vitrectomy or ranibizumab injection (0.5mg/0.05ml) at the end of vitrectomy
Study: NCT04975100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo and SSRI
Description: Patients in the control group will get identical-looking capsules containing placebo in addition to SSRI at an once daily dose
Study: NCT05437432

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VITA AMBRIA
Description: 25 onlay restroations will be fabricated from Vita-ambria glass ceramic press system.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPS e.max press
Description: 25 onlay restroations will be fabricated from IPS e.max glass ceramic press system.
Study: NCT04960293

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uterine artery embolization using spherical gelfoam
Description: Uterine artery embolization is performed using spherical gelfoam. All other processes are same.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uterine artery embolization using tri-acryl gelatin microsphere
Description: Uterine artery embolization is performed using tris-acryl gelatin microsphere. All other processes are same.
Study: NCT05677620

Intervention type: RADIATION
Intervention: Pharyngeal Computed Tomography
Description: To assess the presence of a possible level/level of collapse, a pharyngeal CT with cephalometry will be performed, and a standard classification system, VOTE, will be used. After obtaining said CT, the dentist will place the recording in MCP and perform a new CT scan of the pharynx with cephalometry and with the MCP recording set intraorally to assess whether this position reduces or eliminates the collapse from UA.

Intervention type: RADIATION
Intervention: Pharyngeal Computed Tomography
Description: To assess the presence of a possible level/level of collapse, a pharyngeal CT with cephalometry will be performed, and a standard classification system, VOTE, will be used. After obtaining said CT, the dentist will place the recording in MCP and perform a new CT scan of the pharynx with cephalometry and with the MCP recording set intraorally to assess whether this position reduces or eliminates the collapse from UA.

Intervention type: DRUG
Intervention: Drug-Induced Sleep Endoscopy (Propofol)
Description: The DISE technique will be performed by an otorhinolaryngologist (ENT) with a nasopharyngoscope in a operating room. This technique is complemented with bite registration (MCP). Artificial sleep will be induced by intravenous administration of propofol through an infusion system controlled by an anesthesiologist (2.0-3.0 mcg/mL). The following variables will be continuously monitored: electrocardiography, oxygen saturation, and bispectral index (BIS). In this phase of the DISE, the upper airways will be evaluated during sleep with the MCP positioned intra-orally.
Study: NCT06257381

Intervention type: OTHER
Intervention: VO2max
Description: Overall design 16 non-smoking individuals with COPD and 16 controls (non-smokers) matched for age and sex on a group level will be included in the study. The study consists of two study days. Separation between the study days are at least 48 hours and maximum 10 days.~Before entering the study: Informed written and oral consent.~Study day 1: Medical examination, full lung function testing (dynamic spirometry, whole-body plethysmography, diffusion capacity) followed by a maximal oxygen consumption test (VO2peak), VO2-verification bout and VO2kinetic test (duration 3h).~Study day 2: Participants will undergo a maximal oxygen consumption test (VO2peak), VO2-verification bout and VO2kinetic test (duration 1,5h).

Intervention type: OTHER
Intervention: VO2max
Description: Overall design 16 non-smoking individuals with COPD and 16 controls (non-smokers) matched for age and sex on a group level will be included in the study. The study consists of two study days. Separation between the study days are at least 48 hours and maximum 10 days.~Before entering the study: Informed written and oral consent.~Study day 1: Medical examination, full lung function testing (dynamic spirometry, whole-body plethysmography, diffusion capacity) followed by a maximal oxygen consumption test (VO2peak), VO2-verification bout and VO2kinetic test (duration 3h).~Study day 2: Participants will undergo a maximal oxygen consumption test (VO2peak), VO2-verification bout and VO2kinetic test (duration 1,5h).
Study: NCT05269095

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia only
Description: Patients will receive spinal anesthesia with 2-3 ml 0.5% (10-15 mg) hyperbaric bupivacaine plus 25 ug fentanyl at the L3/4 interspaces.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia and ultrasound-guided Genicular nerves block
Description: Patients will receive16 ml bupivacaine 0025% will be administered, and4 ml of this solution will be placed at each of the 4 target nerves.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Adductor Canal block (ACB) technique with infiltration of the interspace between popliteal artery and the capsule of posterior knee block ('PACK)
Description: Adductor Canal block (ACB) technique will be performed using 16 ml bupivacaine 0025% As regarding the Popliteal artery and the capsule of posterior knee block ('PACK), it will be performed Using 16 ml bupivacaine 0.25%
Study: NCT06008184

Intervention type: OTHER
Intervention: 24 hours sampling of 4 biological fluids (blood, ISF, sweat and saliva)
Description: 24 hours sampling of 4 biological fluids:~* blood: sampling every 20 minutes (through a venous catheter)~* ISF: automated sampling every 20 minutes (microdialysis technique connected to U-Rhythm device)~* Sweat : collection of 1 to 3 samples at 4 differents timepoints~* Saliva : sampling every hour (except during the night)

Intervention type: OTHER
Intervention: 24 hours sampling of ISF or sweat (after validating the correlation with blood)
Description: 24 hours sampling in an ambulatory setting
Study: NCT05040074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SQ-Kyrin Transcatheter Edge-to-Edge Valve Repair System
Description: Transesophageal echocardiography-guided, implantable mitral valve clip repair system
Study: NCT05406102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Patients received an initial dose of 0.1mg/kg of remimazolam (add to 0.05 mg/kg top-ups doses to a total of up to five times within 15minutes).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol group
Description: Patients received an initial dose of 1.5mg/kg of propofol(add to 0.5 mg/kg top-ups doses to a total of up to five times within 15minutes).
Study: NCT05151757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A standard image training set
Description: The standard image training set will consist of about 50 normal optic nerve images of people without glaucoma and about 50 images of people with glaucoma. Training is done in 3 modules.
Study: NCT03810911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin
Description: Used to treat anemia. In the group labeled no intervention, the intervention is simply delayed 12 weeks after randomization as noted in the description.
Study: NCT05121376

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose 1 of BMN 331
Description: BMN 331 AAV Gene Therapy

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose 2 of BMN 331
Description: BMN 331 AAV Gene Therapy

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose 3 of BMN 331
Description: BMN 331 AAV Gene Therapy
Study: NCT04896476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EchoMark
Description: The EchoMark is to be secured a minimum of 3 cm away from the anastomosis.
Study: NCT05107622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMUD+Probiotic
Description: Full-mouth ultrasonic periodontal debridement associated with administration of probiotic formulation (Lactobacillus paracasei 28.4) twice a day for 30 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: FMUD+Placebo
Description: Full-mouth ultrasonic periodontal debridement associated with administration of placebo formulation twice a day for 30 days.
Study: NCT06641180

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Dose trivalent influenza vaccine (Split virion, Inactivated)
Description: Liquid suspension for intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-dose trivalent influenza vaccine (Split virion, Inactivated)
Description: Liquid suspension for intramuscular injection
Study: NCT06224764

Intervention type: OTHER
Group type: OTHER
Intervention: Mother and Father questionnaires
Description: Mother and Father questionnaires (on paper or by phone) and data collectionon newborns weighing less than 2 kilos (at discharge from birth to 11 months)
Study: NCT05677620

Intervention type: DRUG
Intervention: Drug-Induced Sleep Endoscopy (Propofol)
Description: The DISE technique will be performed by an otorhinolaryngologist (ENT) with a nasopharyngoscope in a operating room. This technique is complemented with bite registration (MCP). Artificial sleep will be induced by intravenous administration of propofol through an infusion system controlled by an anesthesiologist (2.0-3.0 mcg/mL). The following variables will be continuously monitored: electrocardiography, oxygen saturation, and bispectral index (BIS). In this phase of the DISE, the upper airways will be evaluated during sleep with the MCP positioned intra-orally.

Intervention type: DEVICE
Intervention: Mandibular Advancement Device
Description: A duo-block, titratable, and customized MAD (NOA®; Orthoapnea) will be fitted for each patient who starts treatment with MAD. The MAD consists of two CAD/CAM polyamide intraoral devices (one for the upper and one for the lower arch). The adaptation period takes place over one month. After this adaptation, patients will undergo a new PSG using MAD.

Intervention type: DEVICE
Intervention: Mandibular Advancement Device
Description: A duo-block, titratable, and customized MAD (NOA®; Orthoapnea) will be fitted for each patient who starts treatment with MAD. The MAD consists of two CAD/CAM polyamide intraoral devices (one for the upper and one for the lower arch). The adaptation period takes place over one month. After this adaptation, patients will undergo a new PSG using MAD.

Intervention type: DEVICE
Intervention: Mandibular Advancement Device
Description: A duo-block, titratable, and customized MAD (NOA®; Orthoapnea) will be fitted for each patient who starts treatment with MAD. The MAD consists of two CAD/CAM polyamide intraoral devices (one for the upper and one for the lower arch). The adaptation period takes place over one month. After this adaptation, patients will undergo a new PSG using MAD.
Study: NCT05121376

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose 4 of BMN 331
Description: BMN 331 AAV Gene Therapy

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose 5 of BMN 331
Description: BMN 331 AAV Gene Therapy

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose 6 of BMN 331
Description: BMN 331 AAV Gene Therapy

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose 7 of BMN 331
Description: BMN 331 AAV Gene Therapy
Study: NCT04945044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computed adenoma detection system (CADe)
Description: This is a computed system that helps the endoscopist to increase the detection of colorectal polyps

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group (regular colonoscopy)
Description: It is exclusively the endoscopist in charge of the detection of the polyps (usual practice)
Study: NCT05843149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manual Therapy/Exercises
Description: Three individual therapy sessions and nine group sessions manual therapy/exercises of 60 min. duration under the guidance of a trained therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy/Back School
Description: Three individual therapy sessions and nine group sessions physiotherapy/back school of 60 min. duration under the guidance of a trained therapist.
Study: NCT04906785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-385
Description: Test Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-385
Description: Test Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D744
Description: Reference Drug
Study: NCT06200207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziltivekimab
Description: Zilitivekimab will be administered subcutaneously once-monthly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to ziltivekimab will be administered subcutaneously once-monthly.
Study: NCT04906785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D744
Description: Reference Drug
Study: NCT06354725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric
Description: Players were randomly assigned to a two-times-a-week (2PLYO, n = 15) or four-times-a-week (4PLYO, n = 15) PT group. Both groups performed the same weekly total volume of jumps during PT in addition to regular basketball training and competition. After the eight-week intervention, all players underwent a one-week detraining period with no PT training while basketball training and competitions continued. Testing was performed at baseline (pre-test), after intervention (post-test), and after the detraining period. Players were assessed for lower body power using jump tests (countermovement jump \[CMJ\], drop-jump \[DJ\] from a 20-cm box, and horizontal jump \[HJ\]; change of direction ability using a planned agility test; and speed using a 20-m sprint and a 5-m split.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric
Description: Players were randomly assigned to a two-times-a-week (2PLYO, n = 15) or four-times-a-week (4PLYO, n = 15) PT group. Both groups performed the same weekly total volume of jumps during PT in addition to regular basketball training and competition. After the eight-week intervention, all players underwent a one-week detraining period with no PT training while basketball training and competitions continued. Testing was performed at baseline (pre-test), after intervention (post-test), and after the detraining period. Players were assessed for lower body power using jump tests (countermovement jump \[CMJ\], drop-jump \[DJ\] from a 20-cm box, and horizontal jump \[HJ\]; change of direction ability using a planned agility test; and speed using a 20-m sprint and a 5-m split.
Study: NCT04939727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OUD-CDS + Suicide Risk Model associated CDS
Description: Access to OUD-CDS + Suicide Risk CDS
Study: NCT06222437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: effectiveness of semaglutide in PCOS
Study: NCT05351411

Intervention type: OTHER
Description: Participants in the control group maintained their therapeutic routine and had the opportunity to take part in the combined progressive functional exercise intervention after follow-up assessments had been conducted.
Study: NCT04917913

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Digestive enzyme blend
Description: Subjects will take 3 capsules (one per meal) of digestive enzymes (50mg) daily for 30 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take 3 capsules (one per meal) of a placebo (50mg) daily for 30 days.
Study: NCT05251948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab is administered by IV infusion on Day 1 of each 21 day cycle. Treatment until progressive disease.
Study: NCT05290116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC Combined with Tislelizumab and Apatinib
Description: Hepatic Arterial Infusion Chemotherapy: FOLFOX6 regimen was infused with chemotherapy drugs: oxaliplatin 130 mg/m2 infusion for 2 hours, folinate calcium 400 mg/m2 infusion for 2 hours, 5-fluorouracil 400 mg/m2 arterial infusion for 10 minutes, 5-fluorouracil 1200 mg/m2 infusion for 23 hours. Every 3 weeks, no more than 4 cycles of HAIC treatment.~Tislelizumab and Apatinib treatment: start at 0-3 days after the end of hepatic arterial infusion chemotherapy: Tislelizumab 200 mg, ivdrip, Q3W; Apatinib 250 mg, po, QD.
Study: NCT05068219

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual physical therapy
Description: Standard rehabilitation for diaphragmatic paresis~* EFA (Expiratory Flow Acceleration) at the upper thoracic level.~* PEP (Positive Expiratory Pressure).~* Expectoration if necessary (coughing up and spitting out)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual physical therapy
Description: Standard rehabilitation for diaphragmatic paresis~* EFA (Expiratory Flow Acceleration) at the upper thoracic level.~* PEP (Positive Expiratory Pressure).~* Expectoration if necessary (coughing up and spitting out)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contract-Relax technique
Description: The diaphragmatic CR is done in a semi-sitting position.~The CR is composed of 4 steps :~* First maximum inspiration expiration with position of the hands of the physiotherapist on the last ribs and without resistance (Goal: taking rhythm).~* Second maximum inspiration expiration : Free inspiration, expiration with pressure on the last ribs to bring the diaphragm into internal stroke.~* Maximum inspiration against resistance, then maximum expiration with increased pressure.~* Maximum inspiration with dynamic release of resistance (Goal: hyperextension of the diaphragm) followed by maximum expiration with resistance to allow an increase in expiratory flow.
Study: NCT04897178

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Routine 2 dimensional Ultrasound used to screen fetuses for congenital anomalies

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Routine 2 dimensional Ultrasound used to screen fetuses for congenital anomalies
Study: NCT05251948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is administered by IV infusion on Day 1 of each 21 day cycle. Treatment until progressive disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine is administered orally twice daily on Days 1-14 of each 21 day cycle. Treatment for up to six cycles.
Study: NCT05860218

Intervention type: OTHER
Group type: OTHER
Intervention: advices
Description: The following advice will be given to the patients :~1. Walking as flexibly (normally) as possible~2. Advise when lifting ;~   * avoid twisting and bending.~  * for heavy objects use thighs with a vertical back.~  * at other times, use the back and flex it.~3. Heat application for 20 mins twice /day .~4. Avoid sitting or standing for prolonged period and change position every 15 mins.~5. Sitting: Sit with a back support~6. Driving: Use a back support (lumbar roll) at the curve of your back.~7. Sleeping and lying down: Select a firm mattress and box spring set that does not sag. If necessary, place a board under your mattress. You can also place the mattress on the floor temporarily if necessary.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: advices
Description: The following advice will be given to the patients :~1. Walking as flexibly (normally) as possible~2. Advise when lifting ;~   * avoid twisting and bending.~  * for heavy objects use thighs with a vertical back.~  * at other times, use the back and flex it.~3. Heat application for 20 mins twice /day .~4. Avoid sitting or standing for prolonged period and change position every 15 mins.~5. Sitting: Sit with a back support~6. Driving: Use a back support (lumbar roll) at the curve of your back.~7. Sleeping and lying down: Select a firm mattress and box spring set that does not sag. If necessary, place a board under your mattress. You can also place the mattress on the floor temporarily if necessary.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises plus advices
Description: In addition to the same advice of group A, a suggested functional exercise will be performed for this group.~1. Sidestepping against band resistance:~2. The quadriped opposite arm leg aganist resistance .~3. Squat row on a balance board with band resistance:~4. Front raise single leg support with band resistance:~5. The Advanced Prone Bridge:~6. Side sliding on a fitter board (lateral lunge with band):
Study: NCT06299462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG 5.0
Description: ATG 2.5 mg/kg on days -2 and -1